Invion Ltd. · ASX:IVX
Invion — Investor Presentation (February 2018)
37 slides from Invion's investor presentation, Feb 12, 2018
Slide 1: Invion Corporate Presentation February 2018
For personal use only INVION CORPORATE PRESENTATION February 2018 1
Slide 2: Disclaimers
DISCLAIMERS For personal use only This investor presentation (Presentation) has been prepared by Invion Limited (the Company or Invion). It contains general information about the Company as at the date of this Presentation and the proposed non-renounceable pro-rata entitlement offer to be made by th
Slide 3: R&D Services Agreement and Licence Agreements with Cho Group
R&D Services Agreement: STRATEGIC Invion will conduct clinical development of Photosoft™ globally, For personal use only leveraging the Company’s expertise. TRANSACTION The Cho Group will provide non- dilutive funding for R&D and clinical trials as part of a global development strategy for the asset
Slide 4: What is Photo Dynamic Therapy (PDT)?
For personal use only WHAT IS PHOTO DYNAMIC THERAPY (PDT)? Use of light to destroy cancerous cells or other abnormal tissue When exposed to specific wavelengths of light, photosensitizing agents produce a form of oxygen that causes destruction of nearby cells without damaging nearby tissue Wavelengt
Slide 5: What is Photodynamic Therapy?
WHAT IS PHOTODYNAMIC For personal use only THERAPY? Photodynamic therapy (PDT) was developed at Roswell Park Cancer Institute (RPCI) in the late 1970s by Thomas Dougherty, PhD PDT is a treatment that uses a light sensitive drug – a photosensitiser - and non-thermal visible red light, typically gener
Slide 6: How PDT Works
For personal use only Photosensitizing 1 HOW PDT agent is taken (by mouth) or given (intravenously) The agent circulates through 2 WORKS the body and concentrates at the site of the tumour Light of specific wavelengths is 3 shone on the body which activates the reaction in the tumour The tumour is 4
Slide 7: PDT Mechanism of Action
PDT MECHANISM For personal use only OF ACTION PHOTODYNAMIC THERAPY (PDT) uses non-toxic photosensitisers and harmless visible light in combination with oxygen to produce cytotoxic reactive oxygen species that kill malignant cells by apoptosis and/or necrosis, shut down the tumour microvasculature an
Slide 8: PDT in Practice
PDT IN PRACTICE For personal use only PDT IS USUALLY PERFORMED AS AN OUTPATIENT PROCEDURE There are a number of clinics throughout Australia that offer PDT therapy for the treatment of superficial skin cancers, and sunspots, including solar keratoses PDT may be repeated and may be used with other th
Slide 9: History of Photodynamic Therapy
HISTORY OF For personal use only PHOTODYNAMIC THERAPY 1903 1904 1930 1942 1958 Nobel Prize Von Tappeiner: Nobel Prize Porphrins: Light Bed therapy N. Finsen: PD reaction first H. Fischer: First used in for Neonatal Light therapy shown Porphyrins treatments Jaundice for skin description conditions 9
Slide 10: History of PDT 1971-2006
For personal use only 1971-85 1990 2006 Dougherty: Russian and Windahl et al. Moore & Photofrin Chinese PDT (Denmark): PDT Emberton therapy developments for local (England): NASA & RSA prostate Interstitial cancer prostate PDT 10
Slide 11: First Generation Photosensitizers
For personal use only PDT therapy became ‘mainstream’ in Variants of 1995 with the FDA Photofrin Tended to remain approval of Photofrin were in the body for (porfimer sodium) subsequently long periods for treatment developed in of esophageal clinical trials cancer HOWEVER FIRST Does not absorb GENER
Slide 12: Second Generation Photosensitizers
For personal use only Strong absorption Water soluble and longer Largely with good chlorophyll wavelengths tissue allowing deeper based distribution penetration of tissues Low circulation BETTER times so patients Different TUMOR are not left chemistry SPECIFICITY vulnerable to SECOND sunlight damage
Slide 13: Research Output: MD Anderson Centre
RESEARCH OUTPUT: MD ANDERSON CENTRE For personal use only Clinical studies revealed that PDT can be curative, particularly in early stage tumors. It can prolong survival in patients with inoperable cancers and significantly improve quality of life. Minimal normal tissue toxicity, negligible systemic
Slide 14: New Wave of Interest with Tookad
NEW WAVE OF INTEREST WITH TOOKAD For personal use only STEBA BIOTECH CONDUCTED PH III IN 208 “Localised, low-risk prostate cancer can be PATIENTS WITH LOW-RISK PROSTATE CANCER: treated in a way that not only preserves genitourinary function but also results in a TOOKAD ACTIVE lower progression rate,
Slide 15: New Generation Photo Dynamic Therapy: Photosoft
NEW GENERATION For personal use only PHOTO DYNAMIC THERAPY: PHOTOSOFT™ Invion has licensed an asset based on patented PDT agent Photosoft™ Targeted to address limitations of 1st Generation PDT therapies Uses a laser light activation method based on a short, pulsating Near Infrared (NIR) wavelengths
Slide 16: Photosoft
PHOTOSOFT™ For personal use only Chlorophyll-based PDT photosensitiser Complex of chlorin and chlorophyllin ACTIVATES AT MULTIPLE SENSITIVITY RANGES ACROSS A BROAD SPECTRUM 16
Slide 17: Currently Available Photosoft Therapies
CURRENTLY AVAILABLE PHOTOSOFT™ THERAPIES For personal use only PHOTOSOFT™ ADVANTAGES 1 Activation at multiple ranges allows deeper tissue penetration for the light source Water soluble Good bioavailability – can be administered 2 sublingually and intravenously Chlorin-e6 and Chlorophyllin-A are used
Slide 18: 1st Generation vs Photosoft
1ST GENERATION VS PHOTOSOFT™ For personal use only LIMITATION 1ST GENERATION PDT PHOTOSOFT™ Fast body clearance time from normal cells and tissue structures as well CLEARANCE 2 to 3 months clearance time. This causes extreme light sensitivity as organs. Combined with high cancer cell selectivity all
Slide 19: Localised Prostate Cancer: The State of Play
LOCALISED PROSTATE CANCER: For personal use only THE STATE OF PLAY INCREASING NUMBERS OF MEN ARE CHOOSING ACTIVE SURVEILLANCE OVER SURGERY OR RADIOTHERAPY BECAUSE OF THE RISKS OF THESE TREATMENTS Active surveillance was ~6% of US patients 15 years ago, now 40% Surgery and radiotherapy are radical tr
Slide 20: Early Studies of Photosoft Conducted in Australia
EARLY STUDIES OF PHOTOSOFT™ CONDUCTED IN AUSTRALIA For personal use only PHASE I | PROSTATE CANCER 2013 2017 o Photosoft™ was administered to 68 prostate cancer patients by o A second Phase I was completed in 37 patients by Donald Urologist Donald Murphy and collaborators Murphy in collaboration wit
Slide 21: A New Wave: Immunotherapy and PDT
A NEW WAVE: IMMUNOTHERAPY For personal use only AND PDT Immune response is important in the control of tumour 2013 2017 growth o Photosoft was administered to 68 prostate cancer patients by o A second Phase I was completed by Donald Murphy in Urologist Donald Murphy and collaborators collaboration w
Slide 22: Phase I Prostate Cancer Data
PHASE I PROSTATE CANCER DATA For personal use only 86 proteins relating to immune responses were observed Proteins relating to certain immune response pathways are enriched and were significantly over-represented within the dataset 22
Slide 23: Advantages of NGPDT and Photosoft
For personal use only ADVANTAGES OF NGPDT AND PHOTOSOFT™ The immune response observed by Murphy in the Phase I provides potential advantages over other water-soluble PDT therapies such as Tookad There is a growing body of knowledge that PDT has the potential to generate an anti-cancer immune respons
Slide 24: Targets
TARGETS For personal use only Skin cancers including melanoma, squamous cell carcinoma & basal PDT THERAPIES cell carcinoma TARGET EARLY-STAGE Lung cancer TREATMENT AS NON-INVASIVE Prostate or Ovarian cancer AND REPEATABLE 24
Slide 25: First Steps: Funded with Non-Dilutive Capital
For personal use only FIRST STEPS: FUNDED WITH NON-DILUTIVE Establish Scientific Explore short term Develop ovarian CAPITAL Advisory Board, opportunities for cancer strategy as and timing/ costs of treatment of skin the next clinical Phase II/ III clinical cancers and other opportunity for trials in
Slide 26: Acquisition/Licensing Opportunities
For personal use only ACQUISITION/ LICENSING OPPORTUNITIES INV103 (Cpn10) INV102 (Nadolol) INV104 (Zafirlukast) Current assets have completed programmed clinical development Management remains committed to licensing the assets 26
Slide 27: Entitlement Offer Detail
ENTITLEMENT OFFER DETAIL For personal use only FULLY UNDERWRITTEN NON-RENOUNCEABLE ENTITLEMENT OFFER Entitlement Offer Ratio 8 for 27 Approximate amount raised $2.5 million CAPITAL STRUCTURE Current Shares on Issue 4,205,965,273 Entitlement Offer Shares 1,246,211,933 Post Entitlement Offer Shares on
Slide 28: Key Dates
KEY DATES For personal use only This timetable is indicative only and subject to change. The Directors may vary these dates, in consultation with the Underwriter, subject to the Listing Rules. An extension of the Closing Date will delay the anticipated date for issue of the New Shares. The Directors
Slide 29: Use of Funds
USE OF FUNDS For personal use only $ Working capital to fund current and forward operations 0.9M Repayment of current liabilities: outstanding loans and all accrued interest 1.6M TOTAL 2.5M 29
Slide 30: Key Risks
KEY RISKS For personal use only This section sets out some of the key risks to an investment in Invion Limited (Invion or Company). The risks in this section are not, and should not be considered to be or relied on as, an exhaustive list of the risks relevant to an investment in Invion. The risks ar
Slide 31: Key Risks
KEY RISKS For personal use only Invion has entered into an exclusive distribution and licence agreement with RMW Cho Group in relation to, amongst other things, the distribution and commercialisation of the Next Generation PDT (NGPDT) technology. Failure by Invion to comply with the terms of the NGP
Slide 32: Key Risks
KEY RISKS For personal use only The research, development, manufacture, marketing and sale of products using Invion’s technology are subject to varying degrees of regulation by a number of government authorities in Australia and overseas including but not limited to the FDA. Therapeutic products mus
Slide 33: Key Risks
KEY RISKS For personal use only Invion will need to enter into one or more commercial partnering agreements to launch the marketing and sales of its lead products. The Dependence on success of Invion’s partnering arrangements may depend on the resources devoted to them by itself or its industry part
Slide 34: Key Risks
KEY RISKS For personal use only The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. Invion’s products may compete with existing alternative treatments that are already available to customers. In addition, a number of co
Slide 35: Key Risks
KEY RISKS For personal use only Invion’s operating and financial performance is influenced by a variety of general economic and business conditions, both domestic and General economic global, including the level of inflation, commodity prices, interest rates and government fiscal, monetary and regul
Slide 36: International Selling Restrictions
INTERNATIONAL SELLING RESTRICTIONS For personal use only Hong Kong: WARNING: This document has not been, and will not be, registered in Hong Kong, nor has it been authorised by any regulatory authorities in Hong Kong. The New Shares may not be offered or sold and will not be offered or sold in Hong
Slide 37: Invion
INVION Ajuo osn feuosied 10}